AIM: This study describes, in detail, the phenotype of late-onset retinal macular degeneration (L-ORMD) an inherited condition affecting both the retina and anterior segment. A staging based on clinical characteristics is proposed, and the relevance of this condition to current understanding of age-related macular degeneration is discussed. METHODS: A systematic review of the literature regarding this condition supports a detailed description of the natural history. Clinical experiences in identifying, monitoring and managing patients are also presented. RESULTS: L-ORMD is a rare fully penetrant autosomal dominant condition resulting from a mutation in the C1QTNF5 gene on chromosome 11. Affected individuals develop bilateral loss of vision, dark-adaptation abnormalities, fundus drusen-like yellow spots, midperipheral pigmentation, choroidal neovascularisation, chorioretinal atrophy and long anteriorly inserted lens zonules. Patients may benefit from treatment with high-dose vitamin A. CONCLUSIONS: Raised awareness of L-ORMD should lead to earlier diagnosis and improved care for patients. New antivascular endothelial growth factor treatment may provide a new possibility for management. A deeper insight into molecular and genetic mechanisms of L-ORMD may suggest avenues to explore new treatments of this disorder.
AIM: This study describes, in detail, the phenotype of late-onset retinal macular degeneration (L-ORMD) an inherited condition affecting both the retina and anterior segment. A staging based on clinical characteristics is proposed, and the relevance of this condition to current understanding of age-related macular degeneration is discussed. METHODS: A systematic review of the literature regarding this condition supports a detailed description of the natural history. Clinical experiences in identifying, monitoring and managing patients are also presented. RESULTS: L-ORMD is a rare fully penetrant autosomal dominant condition resulting from a mutation in the C1QTNF5 gene on chromosome 11. Affected individuals develop bilateral loss of vision, dark-adaptation abnormalities, fundus drusen-like yellow spots, midperipheral pigmentation, choroidal neovascularisation, chorioretinal atrophy and long anteriorly inserted lens zonules. Patients may benefit from treatment with high-dose vitamin A. CONCLUSIONS: Raised awareness of L-ORMD should lead to earlier diagnosis and improved care for patients. New antivascular endothelial growth factor treatment may provide a new possibility for management. A deeper insight into molecular and genetic mechanisms of L-ORMD may suggest avenues to explore new treatments of this disorder.
Authors: Astra Dinculescu; Seok-Hong Min; Frank M Dyka; Wen-Tao Deng; Rachel M Stupay; Vince Chiodo; W Clay Smith; William W Hauswirth Journal: Invest Ophthalmol Vis Sci Date: 2015-10 Impact factor: 4.799
Authors: Tiarnan D L Keenan; Elliott K Vanderford; Tharindu de Silva; Paul A Sieving; Catherine A Cukras Journal: Retina Date: 2021-11-01 Impact factor: 3.975
Authors: Shyamanga Borooah; Vasileios Papastavrou; Leonardo Lando; Jonathan Han; Jonathan H Lin; Radha Ayyagari; Baljean Dhillon; Andrew C Browning Journal: Ophthalmol Retina Date: 2020-12-22
Authors: Chloe M Stanton; Shyamanga Borooah; Camilla Drake; Joseph A Marsh; Susan Campbell; Alan Lennon; Dinesh C Soares; Neeru A Vallabh; Jayashree Sahni; Artur V Cideciyan; Baljean Dhillon; Veronique Vitart; Samuel G Jacobson; Alan F Wright; Caroline Hayward Journal: Sci Rep Date: 2017-09-22 Impact factor: 4.379